On the stock market since 2021, it operates in the world of health and science. It has 73 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $280.7M in the vault; even if every debt were paid off, $280.2M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 4 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $48.3M against $0 in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, GHRS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GHRS is a high-risk stock — not yet profitable, and its future rides on its product catching on.